Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 82.38M P/E - EPS this Y 2.20% Ern Qtrly Grth -
Income -15.07M Forward P/E -6.54 EPS next Y 16.30% 50D Avg Chg 1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -11.00%
Recommedations 2.00 Quick Ratio 1.97 Shares Outstanding 13.77M 52W Low Chg 11.00%
Insider Own 47.16% ROA -72.74% Shares Float 6.34M Beta -
Inst Own 12.19% ROE -147.23% Shares Shorted/Prior 26.69K/19.84K Price 6.02
Gross Margin - Profit Margin - Avg. Volume 121,382 Target Price 14.33
Oper. Margin - Earnings Date - Volume 8,515 Change 0.00%
About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Intensity Therapeutics, Inc. News
11/21/24 Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
11/18/24 Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
11/13/24 Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/13/24 3 US Penny Stocks With Market Caps Under $200M To Watch
11/08/24 Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
10/31/24 Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
09/04/24 Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/08/24 Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07/09/24 Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
06/06/24 Will Intensity Therapeutics (NASDAQ:INTS) Spend Its Cash Wisely?
05/15/24 Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
05/10/24 Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
05/09/24 Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
04/02/24 Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
03/26/24 Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
03/14/24 Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
03/14/24 Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
02/21/24 Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
01/03/24 Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
12/29/23 Intensity Therapeutics (NASDAQ:INTS) Is In A Good Position To Deliver On Growth Plans
INTS Chatroom

User Image NVDAMillionaire Posted - 1 day ago

$INTS Intensity Therapeutics (NASDAQ:INTS): Building a Formidable Pipeline to Tackle Solid Tumors https://beyondspx.com/article/intensity-therapeutics-nasdaqints-building-a-formidable-pipeline-to-tackle-solid-tumors

User Image OpenOutcrier Posted - 11/21/24

$INTS (-5.1% pre) Intensity Therapeutics (INTS) Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - SI https://ooc.bz/l/48947

User Image Stmkr Posted - 11/21/24

$INTS Has the company discussed how it plans to fung ongoing/planned trials??

User Image Stmkr Posted - 11/21/24

$INTS Just 3M?? Less even than the operating expenses of a single quarter

User Image justiceforb_85 Posted - 11/18/24

$INTS $XBI excellent data for INT230-6 in significantly improving survival across various sarcoma subtypes. https://ir.intensitytherapeutics.com/news-events/press-releases/detail/92/intensity-therapeutics-presents-int230-6-phase-12-data-in

User Image donutfish Posted - 11/17/24

$INTS Anyone see the CTOS presentation they did?

User Image Powderranger Posted - 11/14/24

$INTS sleeping giant

User Image justiceforb_85 Posted - 11/12/24

$INTS would be great to have INT230-6 as an option for STS and TNBC. https://www.curetoday.com/view/first-patient-dosed-in-trial-of-int230-6-for-triple-negative-breast-cancer

User Image justiceforb_85 Posted - 11/08/24

$INTS $XBI looking forward to the news. https://ir.intensitytherapeutics.com/news-events/press-releases/detail/90/intensity-therapeutics-selected-for-oral-podium

User Image IN0V8 Posted - 10/31/24

$INTS Watch H.C. Wainwright initiates coverage with buy rating H.C. Wainwright initiates coverage with target $5

User Image Thestocktraderhubzee Posted - 10/31/24

$INTS Intensity Therapeutics And The Swiss Group For Clinical Cancer Research SAKK Dosed First Patient In Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial

User Image Ianwalsh15 Posted - 10/21/24

$INTS

User Image UPupANDaway2020 Posted - 09/11/24

$INTS log in and register…listen to the audio! Going to Phase 3 Trial. https://journey.ct.events/view/ef21791d-dcfa-4af5-a93b-8ba594c598c6

User Image justiceforb_85 Posted - 08/23/24

$INTS $XBI hoping for positive news on trial for soft tissue sarcoma and TNBC.

User Image ReadyMate Posted - 08/23/24

$PRTG $INTS $BHVN That should have read ‘sad’ instead of ‘sas’

User Image TheDarkPrince Posted - 08/15/24

@HedgeTrade SoftBank pulled out of the deal because INTC is incompetent. .

User Image Stock_Titan Posted - 08/08/24

$INTS Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update https://www.stocktitan.net/news/INTS/intensity-therapeutics-reports-second-quarter-2024-financial-results-aifq60sijw7s.html

User Image Chieftess Posted - 4 months ago

$INTS Think its time to take a starter here - maybe I get some on sale tomorrow ;) Good Luck Bulls!

User Image NVDAMillionaire Posted - 4 months ago

$INTS INTS: Intensity Therapeutics Poised for Breakthrough in Cancer Treatment http://beyondspx.com/2024/08/02/ints-intensity-therapeutics-poised-for-breakthrough-in-cancer-treatment/

User Image NVDAMillionaire Posted - 07/12/24

$INTS Intensity Therapeutics, Inc. (NASDAQ:INTS): Pioneering a Novel Approach to Cancer Treatment http://beyondspx.com/2024/07/11/intensity-therapeutics-inc-nasdaqints-pioneering-a-novel-approach-to-cancer-treatment/

User Image Stock_Titan Posted - 07/09/24

$INTS Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma https://www.stocktitan.net/news/INTS/intensity-therapeutics-inc-announces-first-patient-dosed-in-its-01j9r2tgz5cj.html

User Image DonCorleone77 Posted - 5 months ago

$INTS Intensity Therapeutics files to sell 394.5K shares of common stock for holders

User Image DonCorleone77 Posted - 5 months ago

$INTS Intensity Therapeutics files $150M mixed securities shelf

User Image JSTJ Posted - 06/21/24

$INTS Rough end of the week 🥴

User Image Tjcmd Posted - 05/19/24

$INTS So Novo bought Emisphere for the technology will INTS need a licensing agreement with Novo?

User Image Carl_K Posted - 05/16/24

$AGEN $INTS may be one to look into. "Data from that same trial presented at CTOS in November 2023 and ASCO 2023 in June 2023 showed a disease control rate of 93% for subjects on INT230-6 alone, and median overall survival of 21.5 months. Disease control rate measures the percentage of patients who have achieved stable disease, partial response or complete response. In comparison, Agenus' (AGEN) combination therapy of immune-activating botensilimab and anti-PD-1 checkpoint inhibitor balstilimab, looked at as a very interesting drug candidate for a multitude of solid tumors, has a disease control rate of 63% in a Phase 1b trial, with a median of three prior lines of therapy. INT230-6's 93% disease control rate is well above that, for the same indication." https://seekingalpha.com/article/4693038-intensity-therapeutics-a-bargain-for-a-late-stage-company-with-a-remarkable-oncology-drug

User Image Carl_K Posted - 05/14/24

$INTS Article in Seeking Alpha's Must Read digest. https://seekingalpha.com/article/4693038-intensity-therapeutics-a-bargain-for-a-late-stage-company-with-a-remarkable-oncology-drug

User Image jvitalis Posted - 05/14/24

$INTS The final nail on the coffin will be the Chinese government tariffs on Tesla. Key top managers are abandoning the sinking ship and Tesla is desperately hanging on with lies, smokescreens, and mirrors. Compared to last quarter: EPS down 85.2%, Revenues down 15.4%, Operating Margins down 33% and Free Cash Flow down 223%!!! The same goes for Trailing Twelve Months year over year, all above indicators are down from -2% to -68%! In general production, profit margins, and revenues are declining and FSD lawsuits as well as expenses are going up. The competition has caught up and the profit margins will continue to shrink. This is no longer a growth stock and should be priced like GM and Ford at 5-15x Price to Earnings and not at 45x, which means the stock price should be between $20-$60.

User Image ButterCapital Posted - 05/13/24

$INTS 👀

User Image jvitalis Posted - 05/10/24

$INTS Corporate Update In mid-2024, the Company intends on initiating a Phase 3 open-label, randomized study, or the INVINCIBLE-3 Study, testing INT230-6 as a monotherapy compared to the standard of care ("SOC") drugs in second and third line treatment for certain soft tissue sarcoma subtypes. We plan to enroll 333 patients with an endpoint of overall survival and have screened and qualified over 30 sites for the INVINCIBLE-3 Study. In mid-2024, the Company intends on initiating a Phase 2/3 program testing INT230-6 in combination with the SOC treatment (chemotherapy/immunotherapy) compared to SOC alone in women with triple negative breast cancer in presurgical (neoadjuvant) breast cancer. The endpoint for the Phase 2 portion of the study, or the INVINCIBLE-4 Study, is the change in the pathological complete response rate for the combination compared to the SOC alone. We expect to initiate the INVINCIBLE-4 Study in mid-2024, which will provide data to size a Phase 3 study.

Analyst Ratings
Benchmark Speculative Buy Jul 11, 24
Benchmark Speculative Buy May 16, 24
Benchmark Speculative Buy Mar 21, 24
Benchmark Speculative Buy Nov 14, 23
Benchmark Speculative Buy Aug 24, 23
Benchmark Speculative Buy Jul 18, 23